Engineering the exosomal surface with modified GAPDH protein for targeted nucleic acid delivery

Applications: Gene therapy, targeted drug delivery

Exosome surfaces naturally have Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein binding sites. Engineered GAPDH can be used to aid the binding of nucleic acids to an exosome, resulting in their targeted delivery to cells and tissues around the body.

Features	Benefits
Natural presence of GAPDH binding sites on exosomal surface	Uniform loading of nucleic acids into exosome Homogenous exosome population No genetic modification of host cells required
Loads therapeutic RNAs into patient-derived extracellular vesicles(EVs)	Reduces chance of an immune response
E. coli can express GADPH in large quantities	Guarantees GADPH is readily available for commercial development
GAPDH binding sites are universally present on EVs	Allows different sources of EVs to be used for nucleic acid delivery
Binding of GAPDH to exosomes is highly specific and efficient	Ensures nucleic acids are consistently transported effectively
Potential for use in loading exosomes with siRNA, proteins, small molecule drug inhibitors, CRISPR or gRNA	Large range of uses which can be applied to many purposes

Patented & available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

Engineering the exosomal surface with modified GAPDH protein for targeted nucleic acid delivery

Ready to get in touch?